T1	PROC 46 83	Estudio de la eficacia y la seguridad
T2	DISO 105 121	colitis ulcerosa
#1	AnnotatorNotes T2	C0009324; Ulcerative Colitis; Disease or Syndrome
T3	PROC 144 213	Estudio de prolongación de fase 3, multicéntrico, sin enmascaramiento
T4	PROC 220 254	evaluar la eficacia y la seguridad
#2	AnnotatorNotes T4	C0511730; Identify product efficacy and safety issues; Health Care Activity
T5	CHEM 272 283	mirikizumab
#3	AnnotatorNotes T5	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	DISO 301 317	colitis ulcerosa
#4	AnnotatorNotes T6	C0009324; Ulcerative Colitis; Disease or Syndrome
T7	DISO 368 384	Colitis ulcerosa
#5	AnnotatorNotes T7	C0009324; Ulcerative Colitis; Disease or Syndrome
T8	DISO 411 427	Colitis ulcerosa
#6	AnnotatorNotes T8	C0009324; Ulcerative Colitis; Disease or Syndrome
T9	CHEM 87 98	mirikizumab
#7	AnnotatorNotes T9	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	PROC 510 527	estudio de fase 2
T11	PROC 600 611	tratamiento
#8	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	PROC 658 675	estudio de fase 3
T13	PROC 748 759	tratamiento
#9	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	CHEM 764 775	mirikizumab
#10	AnnotatorNotes T14	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T15	PROC 977 988	tratamiento
#11	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	DISO 1063 1066	AAG
#12	AnnotatorNotes T16	C1519255; Serious Adverse Event; Finding
T17	DISO 1107 1117	enfermedad
#13	AnnotatorNotes T17	C0012634; Disease; Disease or Syndrome
T18	PROC 1203 1214	tratamiento
#14	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	PROC 837 860	medidas anticonceptivas
T20	PROC 1322 1335	diagnosticado
#15	AnnotatorNotes T20	C0011900; Diagnosis; Diagnostic Procedure
T21	DISO 1346 1356	enfermedad
#16	AnnotatorNotes T21	C0012634; Disease; Disease or Syndrome
T22	DISO 1371 1390	neoplasias malignas
#17	AnnotatorNotes T22	C0006826; Malignant Neoplasms; Neoplastic Process
T23	DISO 1405 1422	neoplasia maligna
#18	AnnotatorNotes T23	C0006826; Malignant Neoplasms; Neoplastic Process
T24	CHEM 993 1004	mirikizumab
#19	AnnotatorNotes T24	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T25	CHEM 1219 1230	mirikizumab
#20	AnnotatorNotes T25	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T26	CHEM 1540 1551	mirikizumab
#21	AnnotatorNotes T26	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T27	PROC 1640 1653	diagnosticado
#22	AnnotatorNotes T27	C0011900; Diagnosis; Diagnostic Procedure
T28	DISO 1658 1667	infección
#23	AnnotatorNotes T28	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T29	DISO 1706 1717	hepatitis B
#24	AnnotatorNotes T29	C0019163; Hepatitis B; Disease or Syndrome
T30	DISO 1719 1730	hepatitis C
#25	AnnotatorNotes T30	C0019196; Hepatitis C; Disease or Syndrome
T31	DISO 1736 1740	sida
#26	AnnotatorNotes T31	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T32	DISO 1743 1755	tuberculosis
#27	AnnotatorNotes T32	C0041296; Tuberculosis; Disease or Syndrome
T33	DISO 1757 1759	TB
#28	AnnotatorNotes T33	C0041296; Tuberculosis; Disease or Syndrome
T34	CHEM 616 627	mirikizumab
#29	AnnotatorNotes T34	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T35	PROC 1009 1024	enmascaramiento
#30	AnnotatorNotes T35	C0150108; Blinded; Research Activity
T36	DISO 1732 1735	VIH
#31	AnnotatorNotes T36	C0458074; Human immunodeficiency virus (HIV) status; Finding
T37	Date 13 17	2017
T39	Date 255 268	a largo plazo
T40	LIVB 287 296	pacientes
#32	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	LIVB 484 493	Pacientes
#33	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	LIVB 565 577	investigador
#34	AnnotatorNotes T42	C0035173; Research Personnel; Professional or Occupational Group
T43	LIVB 632 641	Pacientes
#35	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	LIVB 713 725	investigador
#36	AnnotatorNotes T44	C0035173; Research Personnel; Professional or Occupational Group
T45	LIVB 784 791	mujeres
#37	AnnotatorNotes T45	C0043210; Woman; Population Group
T46	LIVB 913 925	investigador
#38	AnnotatorNotes T46	C0035173; Research Personnel; Professional or Occupational Group
T47	LIVB 927 936	pacientes
#39	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T49	Neg_cue 1005 1008	sin
T50	LIVB 1029 1038	Pacientes
#40	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Date 1140 1151	la semana 0
T53	LIVB 1287 1296	Pacientes
#41	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	Spec_cue 1393 1404	sospecha de
T55	Date 1470 1481	la semana 0
T38	LIVB 1604 1617	Participantes
#42	AnnotatorNotes T38	C4554048; Study Participant; Population Group
T48	PROC 1500 1513	reclutamiento
#43	AnnotatorNotes T48	C0242800; Patient Recruitment; Research Activity
T52	Neg_cue 1487 1496	impidiera
T56	PROC 1130 1136	visita
#44	AnnotatorNotes T56	C1512346; Patient Visit; Health Care Activity
A1	Assertion T35 Negated
A2	Assertion T23 Speculated
A3	Status T16 History_of
A4	Status T21 History_of
A5	Status T22 History_of
A6	Status T23 History_of
A7	Status T28 History_of
A8	Status T29 History_of
A9	Status T30 History_of
A10	Status T36 History_of
A11	Status T31 History_of
A12	Status T32 History_of
A13	Status T33 History_of
A14	Assertion T48 Negated
#45	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#46	AnnotatorNotes T39	C0443252; Long-term; Temporal Concept
#47	AnnotatorNotes T10	C0282460; Phase 2 Clinical Trials; Research Activity
#48	AnnotatorNotes T12	C0282461; Phase 3 Clinical Trials; Research Activity
#49	AnnotatorNotes T19	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T57	Neg_cue 941 943	no
T58	Observation 955 972	beneficio clínico
A15	Assertion T58 Negated
T59	Neg_cue 1165 1167	no
T60	Observation 1168 1189	cumplan los criterios
A16	Assertion T60 Negated
R1	Negation Arg1:T57 Arg2:T58	
R2	Negation Arg1:T49 Arg2:T35	
R3	Negation Arg1:T52 Arg2:T48	
T61	Observation 579 595	se beneficiarían
A17	Assertion T61 Speculated
#50	AnnotatorNotes T61	C4049461; Unexpected beneficial therapeutic response; Finding (?)
T62	Observation 727 743	se beneficiarían
A18	Assertion T62 Speculated
#51	AnnotatorNotes T62	C4049461; Unexpected beneficial therapeutic response; Finding (?)
R4	Before Arg1:T11 Arg2:T61	
R5	Used_for Arg1:T34 Arg2:T11	
R6	Before Arg1:T13 Arg2:T62	
R7	Used_for Arg1:T14 Arg2:T13	
R8	Overlap Arg1:T4 Arg2:T39	
R9	Experiences Arg1:T40 Arg2:T5	
R10	Experiences Arg1:T40 Arg2:T6	
T63	Quantifier_or_Qualifier 328 344	moderada a grave
#52	AnnotatorNotes T63	C1299393; Moderate to severe; Qualitative Concept
R11	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T63	
T64	Quantifier_or_Qualifier 438 454	moderada a grave
#53	AnnotatorNotes T64	C1299393; Moderate to severe; Qualitative Concept
T65	Quantifier_or_Qualifier 428 434	activa
#54	AnnotatorNotes T65	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R12	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T65	
R13	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T64	
T66	Quantifier_or_Qualifier 318 324	activa
#55	AnnotatorNotes T66	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R14	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T66	
R15	Experiences Arg1:T41 Arg2:T61	
R16	Experiences Arg1:T41 Arg2:T11	
R17	Experiences Arg1:T43 Arg2:T62	
R18	Experiences Arg1:T45 Arg2:T19	
R19	Experiences Arg1:T43 Arg2:T13	
R20	Experiences Arg1:T47 Arg2:T58	
R21	Before Arg1:T15 Arg2:T58	
R22	Used_for Arg1:T24 Arg2:T15	
R23	Experiences Arg1:T47 Arg2:T15	
R24	Overlap Arg1:T15 Arg2:T35	
R25	Experiences Arg1:T50 Arg2:T16	
R26	Experiences Arg1:T50 Arg2:T17	
R27	Before Arg1:T17 Arg2:T56	
R28	Overlap Arg1:T56 Arg2:T51	
T67	Quantifier_or_Qualifier 1102 1106	otra
#56	AnnotatorNotes T67	C0205394; Other; Qualitative Concept
R29	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T67	
R30	Negation Arg1:T59 Arg2:T60	
R31	Negation Arg1:T59 Arg2:T18	
A19	Assertion T18 Negated
A20	Assertion T25 Negated
R32	Used_for Arg1:T25 Arg2:T18	
R33	Negation Arg1:T59 Arg2:T25	
R34	Experiences Arg1:T50 Arg2:T18	
R35	Experiences Arg1:T53 Arg2:T21	
R36	Experiences Arg1:T53 Arg2:T22	
R37	Experiences Arg1:T53 Arg2:T23	
R38	Speculation Arg1:T54 Arg2:T23	
T68	Quantifier_or_Qualifier 1423 1429	activa
#57	AnnotatorNotes T68	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R39	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T68	
T69	PROC 1073 1080	estudio
A21	Status T69 History_of
#58	AnnotatorNotes T69	C0008976; Clinical Trials; Research Activity
T70	PROC 1520 1527	estudio
A22	Status T70 History_of
#59	AnnotatorNotes T70	C0008976; Clinical Trials; Research Activity
R41	Overlap Arg1:T48 Arg2:T70	
T71	PROC 1442 1449	estudio
A23	Status T71 History_of
#60	AnnotatorNotes T71	C0008976; Clinical Trials; Research Activity
R42	Overlap Arg1:T21 Arg2:T71	
R43	Overlap Arg1:T22 Arg2:T71	
R44	Overlap Arg1:T23 Arg2:T71	
R45	Before Arg1:T21 Arg2:T55	
R46	Before Arg1:T22 Arg2:T55	
R47	Before Arg1:T23 Arg2:T55	
R48	Before Arg1:T21 Arg2:T48	
R49	Before Arg1:T22 Arg2:T48	
R50	Before Arg1:T23 Arg2:T48	
T72	Observation 1566 1598	interrupción de su participación
#61	AnnotatorNotes T72	C0422727; Patient withdrawn from trial; Finding (?)
R51	Causes Arg1:T21 Arg2:T72	
R52	Causes Arg1:T22 Arg2:T72	
R53	Causes Arg1:T23 Arg2:T72	
R54	Experiences Arg1:T38 Arg2:T28	
R55	Experiences Arg1:T38 Arg2:T29	
R56	Experiences Arg1:T38 Arg2:T30	
R57	Experiences Arg1:T38 Arg2:T36	
R58	Experiences Arg1:T38 Arg2:T31	
R59	Experiences Arg1:T38 Arg2:T32	
R60	Experiences Arg1:T38 Arg2:T33	
T73	Quantifier_or_Qualifier 1761 1767	activa
#62	AnnotatorNotes T73	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R61	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T73	
R62	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T73	
T74	PROC 1779 1786	estudio
A24	Status T74 History_of
#63	AnnotatorNotes T74	C0008976; Clinical Trials; Research Activity
R63	Overlap Arg1:T28 Arg2:T74	
R64	Overlap Arg1:T29 Arg2:T74	
R65	Overlap Arg1:T30 Arg2:T74	
R66	Overlap Arg1:T36 Arg2:T74	
R67	Overlap Arg1:T31 Arg2:T74	
R68	Overlap Arg1:T32 Arg2:T74	
R69	Overlap Arg1:T33 Arg2:T74	
T75	Quantifier_or_Qualifier 1668 1691	clínicamente importante
R70	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T75	
R71	Overlap Arg1:T27 Arg2:T74	
R72	Before Arg1:T17 Arg2:T51	
#64	AnnotatorNotes T75	C5209294; Clinical relevance; Intellectual Product
#65	AnnotatorNotes T58	C4049461; Unexpected beneficial therapeutic response; Finding (?)
R40	Experiences Arg1:T53 Arg2:T48	
#66	AnnotatorNotes T60	C4329786; Eligibility Criteria Met By Subject; Finding
A25	Experiencer T40 Patient
A26	Experiencer T41 Patient
A27	Experiencer T42 Other
A28	Experiencer T43 Patient
A29	Experiencer T44 Other
A30	Experiencer T45 Patient
A31	Experiencer T47 Patient
A32	Experiencer T46 Other
A33	Experiencer T50 Patient
A34	Experiencer T53 Patient
A35	Experiencer T38 Patient
